Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
Melina Marmarelis, MD, Thoracic Medical Oncologist, UPenn joins us for an interview about precision medicine for mesothelioma. She discusses biomarker information, such as histology (currently
Hair loss, or alopecia, is often associated with cancer therapies and, in particular, with cytotoxic chemotherapy. While this side effect is most often temporary –
Due to recent advances in cancer treatment, especially in the field of immunotherapy, chemotherapy treatment options for mesothelioma have taken a back seat. However, this
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
